2022
DOI: 10.1038/s41374-021-00679-2
|View full text |Cite
|
Sign up to set email alerts
|

FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE mice atherosclerosis

Abstract: Atherosclerosis is a chronic inflammatory vascular disease, and inflammation plays a critical role in its formation and progression. Elevated serum homocysteine (Hcy) is an independent risk factor for atherosclerosis. Previous studies have shown that fatty acid binding protein 4 (FABP4) plays an important role in macrophage inflammation and lipid metabolism in atherosclerosis induced by Hcy. However, the underlying molecular mechanism of FABP4 in Hcy-induced macrophage inflammation remains unknown. In this stu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
21
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(23 citation statements)
references
References 50 publications
(49 reference statements)
1
21
0
Order By: Relevance
“…Here, we identified eight DEGs, including JAK2, ORM1, RNASE2, TNFSF13B, CYBB, EIF2AK2, CD79B and CAMP . More recently, increased interest in JAKi strategies arose for the need of potential treatments for COVID-19, which is implicated in the activation of CD4 + and CD8 + positive T cells, NK cells and monocytes that cooperate with cytokine storm generated by SARS-COV2 ( 46 , 47 ). Two molecules are mainly under focus of pharmaceutical industry, baricitinib and ruxolitinib ( 23 , 48 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Here, we identified eight DEGs, including JAK2, ORM1, RNASE2, TNFSF13B, CYBB, EIF2AK2, CD79B and CAMP . More recently, increased interest in JAKi strategies arose for the need of potential treatments for COVID-19, which is implicated in the activation of CD4 + and CD8 + positive T cells, NK cells and monocytes that cooperate with cytokine storm generated by SARS-COV2 ( 46 , 47 ). Two molecules are mainly under focus of pharmaceutical industry, baricitinib and ruxolitinib ( 23 , 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…In TFs-mRNA network, JAK2 and STAT2 mediate the signal transduction of more than 50 cytokines and growth factors in many different cell types, which is critical for resisting infection and enforcing barrier functions. JAK2/STAT2 pathway contributes to homocysteine-accelerated macrophage inflammation, adding to the risk for atherosclerosis ( 46 ).…”
Section: Discussionmentioning
confidence: 99%
“…Inhibition of FABP4 in wound macrophages reduces inflammatory cytokine expression, making FABP4 a potent regulatory target for excessive inflammation and wound repair in diabetic patients [ 6 ]. FABP4 plays an important role in macrophage inflammation and lipid metabolism in atherosclerosis [ 3 ]. So its role in cancer may also be associated with macrophages.…”
Section: Discussionmentioning
confidence: 99%
“…Elevated plasma FABP4 concentrations were associated with a slightly higher risk of heart failure in American older adults in a prospective study of 4179 participants [ 2 ]. FABP4 plays an important role in macrophage inflammation and lipid metabolism in atherosclerosis [ 3 ], and serum FABP4 is strongly associated with cardiovascular disease mortality [ 4 ]. Therefore, the pathogenic cause may be related to endoplasmic reticulum stress [ 5 ] and inflammatory cytokines in macrophages [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…All functional subsets of RA CD8 expressed CD36 more often, as well as FABP4 and GPR84, than CNT, and the cell surface expression of FABP4 and GPR84 were especially higher in RA effector and memory subsets. In mice, macrophages polarize towards a pro-inflammatory phenotype upon activation of the JAK/STAT-pathway by FABP4, while an agonist of GPR84 triggered TNF-α production in human peripheral blood mononuclear cells [30,31]. These studies may explain the decrease in the expression of these two transporters in RA patients receiving JAK inhibitor or TNF-blockade therapies.…”
Section: Discussionmentioning
confidence: 99%